Lyell Immunopharma
Lyell Immunopharma's revenue fell 41.0% to $0 million in fiscal 2025. Its operating margin was −748,344.4%, down from −588,122.9% a year earlier. Free cash flow was −$151 million. The diluted share count rose 30.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Lyell Immunopharma lost money in fiscal 2025: a net loss of $274 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 615 | 640 | 546 | 370 | 247 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
| Quick ratio | 13.4x | 17.6x | 16.1x | 7.1x | 5.3x |
Cash flow
Projections
Project Lyell Immunopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $12.5 million of Lyell Immunopharma shares on the open market, and 6 insiders sold $590,340, $274 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | David ShookChief Medical Officer | Sold | 500 | $12.70 | $6,350 | Form 4 |
| Aug 21, 2026 | Lynn SeelyPresident and CEO, Director | Sold | 9,589 | $15.54 | $149,013 | Form 4 |
| Aug 21, 2026 | Gary K. LeeChief Scientific Officer | Sold | 1,457 | $15.54 | $22,642 | Form 4 |
| Aug 21, 2026 | Stephen J. HillChief Operating Officer | Sold | 989 | $15.54 | $15,369 | Form 4 |
| Aug 10, 2026 | Veronica Sanchez BulisVP, Corporate Controller | Sold | 621 | $14.34 | $8,905 | Form 4 |
| Aug 10, 2026 | Lynn SeelyPresident and CEO, Director | Sold | 390 | $14.34 | $5,593 | Form 4 |
| Aug 10, 2026 | Gary K. LeeChief Scientific Officer | Sold | 131 | $14.34 | $1,879 | Form 4 |
| Aug 10, 2026 | Stephen J. HillChief Operating Officer | Sold | 89 | $14.34 | $1,276 | Form 4 |
| Jul 17, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% owner | Sold plan | 10 | $13.70 | $137 | Form 4 |
| Jul 16, 2026 | Innovative Cellular Therapeutics Holdings Ltd10% owner | Sold plan | 10 | $13.73 | $137 | Form 4 |
| Jun 10, 2026 | David ShookChief Medical Officer | Sold | 1,977 | $12.64 | $24,989 | Form 4 |
| May 11, 2026 | Lynn SeelyPresident and CEO, Director | Sold | 388 | $18.91 | $7,337 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −128,084.5% | −267,033.4% | −418,941.0% |
| Altman Z'' | 5.21 | −5.77 | −13.93 |
| Accruals ratio | −8.4% | −29.1% | −29.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Lyell Immunopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma | FY25 | −41.0% | −748,344.4% | −418,900.0% | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1 | 8 | 11 | 85 | 0 | 0 | 0 |
| Revenue growth | — | 1,080.5% | 37.3% | 695.1% | −99.8% | −53.1% | −41.0% |
| Gross profit | — | — | — | — | — | — | — |
| Research and development | 64 | 182 | 139 | 159 | 183 | 172 | 159 |
| Operating income | −102 | −212 | −215 | −187 | −247 | −359 | −269 |
| Net income | −129 | −204 | −250 | −183 | −235 | −343 | −274 |
| Diluted EPS (US$) | −480.80 | −313.80 | −36.80 | −14.80 | −18.70 | −26.23 | −16.06 |
| Diluted shares (millions) | 0 | 1 | 7 | 12 | 12 | 13 | 17 |
| Cash flow | |||||||
| Cash from operations | 40 | −161 | −126 | −170 | −164 | −162 | −150 |
| Capital expenditure | 16 | 52 | 66 | 24 | 3 | 0 | 1 |
| Free cash flow | 23 | −212 | −192 | −194 | −166 | −163 | −151 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 12 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 16 | 33 | 62 | 82 | 47 | 33 | 42 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 97 | 613 | 615 | 640 | 546 | 370 | 247 |
| Debt incl. finance leases | — | — | — | — | — | — | — |
| Total assets | — | 908 | 1,127 | 938 | 750 | 491 | 340 |
| Total liabilities | — | 190 | 198 | 104 | 95 | 108 | 92 |
| Shareholders' equity | −111 | −292 | 930 | 833 | 655 | 383 | 248 |
| Margins and ratios | |||||||
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | −15,538.7% | −2,732.6% | −2,016.7% | −220.9% | −190,006.1% | −588,122.9% | −748,344.4% |
| Net margin | −19,692.1% | −2,636.3% | −2,349.5% | −216.2% | −180,486.1% | −562,285.2% | −762,355.6% |
| Free cash flow margin | 3,565.8% | −2,737.9% | −1,800.5% | −228.9% | −127,984.6% | −266,980.3% | −418,900.0% |
| Rule of 40 (growth + FCF margin) | — | −1,657.4% | −1,763.2% | 466.3% | −128,084.5% | −267,033.4% | −418,941.0% |
| Return on capital | — | — | — | — | — | — | — |
| Return on equity | — | — | −78.5% | −20.8% | −31.5% | −66.1% | −87.0% |
| Return on assets | — | — | −24.6% | −17.7% | −27.8% | −55.3% | −66.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |